Smith & Nephew Announces Agreement with the OREF Regarding Grants to Support Research and Education in Orthopaedics
January 30 2009 - 1:57PM
PR Newswire (US)
MEMPHIS, Tenn., Jan. 30 /PRNewswire-FirstCall/ -- Smith &
Nephew, Inc. (NYSE:SNNNYSE:LSE:NYSE:SN) announced today that its
Orthopaedics Reconstruction Division has entered into a grant
administration agreement with the Orthopaedic Research and
Education Foundation (OREF). Under the agreement, Smith &
Nephew's first with a third-party administrator of grants, OREF
will assist Smith & Nephew in continuing its long-standing
support of research and education in orthopaedics. The multi-year
agreement is unique among the major joint replacement makers in
that it covers graduate medical education, including fellowships
and residency enhancement programs, as well as continuing medical
education (CME) and research. This comprehensive approach gives
Smith & Nephew a platform from which to support consistent
education and innovation in orthopaedics. "Smith & Nephew is
dedicated to the advancement of orthopaedic innovation, education
and patient care," said Joseph M. DeVivo, President of Smith &
Nephew Orthopaedics Reconstruction & Trauma Division.
"Formalizing our relationship with OREF allows Smith & Nephew
to continue supporting orthopaedic research and education in a
comprehensive way while working with an organization dedicated to
its mission, independence, and integrity. OREF's history of working
productively with many orthopaedic societies and institutions makes
this an especially good choice." Under the agreement, which has
been approved by Smith & Nephew's government-appointed monitor,
OREF will help Smith & Nephew establish its annual research and
education support goals, ensure the highest standards of
professionalism and independence for distribution of those funds,
and provide regular reports on the results of those donations,
including a detailed annual summary of donation distribution. "This
agreement benefits Smith & Nephew, orthopaedic researchers and
educators, and most importantly, the patients who rely on quality
orthopaedic care," said Dr. William Cooney, Chairman of the Board
of Trustees of OREF. "This agreement will facilitate industry
support for critical research and educational programs and will
serve as a model for other corporations seeking to support
orthopaedic research and education while avoiding conflicts of
interest. We are very proud of OREF's long-standing commitment to
the orthopaedic specialty, and are especially pleased to work with
Smith & Nephew to move into a new era of service." About Smith
& Nephew Smith & Nephew is a global medical technology
business, specialising in Orthopaedics, including Reconstruction,
Trauma and Clinical Therapies; Endoscopy and Advanced Wound
Management. Smith & Nephew is a global leader in arthroscopy
and advanced wound management and is one of the leading global
orthopaedics companies. Smith & Nephew is dedicated to helping
improve people's lives. The Company prides itself on the strength
of its relationships with its surgeons and professional healthcare
customers, with whom its name is synonymous with high standards of
performance, innovation and trust. The company operates in 32
countries around the world generating annual sales of nearly $3.4
billion. About OREF OREF is a fifty-three year old independent,
non-profit organization that was created specifically to receive
donations from individuals and companies to foster research and
education in orthopaedics. Since its inception, OREF has made
approximately 3,200 grants totaling nearly $88 million to
individuals and organizations. OREF's independent peer review
process to evaluate grant applications is based on the standards of
the National Institutes of Health (NIH). Forward-Looking Statements
This press release contains certain "forward-looking statements"
within the meaning of the US Private Securities Litigation Reform
Act of 1995. In particular, statements regarding planned growth in
our business and in our trading margins discussed under "Outlook"
are forward-looking statements as are discussions of our product
pipeline. These statements, as well as the phrases "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions, are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors (including, but not
limited to, the outcome of litigation and regulatory approvals)
that could cause the actual results, performance or achievements of
Smith & Nephew, or industry results, to differ materially from
any future results, performance or achievements expressed or
implied by such forward-looking statements. Please refer to the
documents that Smith & Nephew has filed with the U.S.
Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith & Nephew's
most recent annual report on Form 20F, for a discussion of certain
of these factors. All forward-looking statements in this press
release are based on information available to Smith & Nephew as
of the date hereof. All written or oral forward-looking statements
attributable to Smith & Nephew or any person acting on behalf
of Smith & Nephew are expressly qualified in their entirety by
the foregoing. Smith & Nephew does not undertake any obligation
to update or revise any forward-looking statement contained herein
to reflect any change in Smith & Nephew's expectation with
regard thereto or any change in events, conditions or circumstances
on which any such statement is based. DATASOURCE: Smith &
Nephew, Inc. CONTACT: Analyst-Investor Inquiries: Liz Hewitt, +44
(0) 20 7401 7646, Media Inquiries: Andrew Burns, +1-901-399-5739, ,
both of Smith & Nephew; Gene R. Wurth, OREF, +1-847-384-4362,
Web site: http://www.smith-nephew.com/
Copyright